In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin

Evidence suggests that the non-psychotropic phytocannabinoid cannabidiol (CBD) has anticancer activity on different cell lines and in animal models. The DNA-damaging drug epirubicin (EPI) is widely used for the treatment of malignant tumours. In this study we examined the effectiveness of CBD admini...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Margarita Zhelyazkova, Nadya Hristova-Avakumova, Lozan Todorov, Georgi Momekov
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	antagonism cannabidiol combination chemotherapy epirubicin free radicals oxidative molecular damage Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/561a735bda53473f927a09373311a1bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:561a735bda53473f927a09373311a1bb
record_format	dspace
spelling	oai:doaj.org-article:561a735bda53473f927a09373311a1bb2021-11-17T14:21:55ZIn vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin1310-28181314-353010.1080/13102818.2021.1996270https://doaj.org/article/561a735bda53473f927a09373311a1bb2021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/13102818.2021.1996270https://doaj.org/toc/1310-2818https://doaj.org/toc/1314-3530Evidence suggests that the non-psychotropic phytocannabinoid cannabidiol (CBD) has anticancer activity on different cell lines and in animal models. The DNA-damaging drug epirubicin (EPI) is widely used for the treatment of malignant tumours. In this study we examined the effectiveness of CBD administered alone and in combination with EPI on HL-60, HL-60/Dox and MCF-7 cell-lines. We applied MTT reduction assay and the bioinformatics model of Chou-Talalay for experimental design of combination chemotherapy to evaluate the anticancer activity of several epirubicin-based combinations with CBD in various treatment regimens. In addition, we studied the efficacy of the co-treatment regimens to induce changes in two in-vitro model systems containing superoxide radical and 2-deoxyribose. We then evaluated the effectiveness of EPI plus CBD. The maximal growth cell inhibition ∼90% in leukemic and breast cancer cells was measured at the peak tested concentrations 2.5 EPI plus 25 CBD, µmol/L. The combination index (CI) value showed the presence of slightly expressed antagonism between EPI and CBD in most cases. The antiproliferative effect of the combination was reduced by only 8–10% vs. the inhibition induced by either EPI or CBD alone. We determined that the slight antagonism correlated positively to the registered dosage and decreased the extent of deoxyribose oxidative damage by using the enhanced chemiluminescent method with superoxide radicals. The therapeutic value of the combination of EPI plus CBD mainly consists of its high antiproliferative effect and the possibility to reduce the total dose on leukaemia-transformed cells by a factor of two. Supplemental data for this article is available online at https://doi.org/10.1080/13102818.2021.1996270 .Margarita ZhelyazkovaNadya Hristova-AvakumovaLozan TodorovGeorgi MomekovTaylor & Francis Grouparticleantagonismcannabidiolcombination chemotherapyepirubicinfree radicalsoxidative molecular damageBiotechnologyTP248.13-248.65ENBiotechnology & Biotechnological Equipment, Vol 35, Iss 1, Pp 1613-1622 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antagonism cannabidiol combination chemotherapy epirubicin free radicals oxidative molecular damage Biotechnology TP248.13-248.65
spellingShingle	antagonism cannabidiol combination chemotherapy epirubicin free radicals oxidative molecular damage Biotechnology TP248.13-248.65 Margarita Zhelyazkova Nadya Hristova-Avakumova Lozan Todorov Georgi Momekov In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin
description	Evidence suggests that the non-psychotropic phytocannabinoid cannabidiol (CBD) has anticancer activity on different cell lines and in animal models. The DNA-damaging drug epirubicin (EPI) is widely used for the treatment of malignant tumours. In this study we examined the effectiveness of CBD administered alone and in combination with EPI on HL-60, HL-60/Dox and MCF-7 cell-lines. We applied MTT reduction assay and the bioinformatics model of Chou-Talalay for experimental design of combination chemotherapy to evaluate the anticancer activity of several epirubicin-based combinations with CBD in various treatment regimens. In addition, we studied the efficacy of the co-treatment regimens to induce changes in two in-vitro model systems containing superoxide radical and 2-deoxyribose. We then evaluated the effectiveness of EPI plus CBD. The maximal growth cell inhibition ∼90% in leukemic and breast cancer cells was measured at the peak tested concentrations 2.5 EPI plus 25 CBD, µmol/L. The combination index (CI) value showed the presence of slightly expressed antagonism between EPI and CBD in most cases. The antiproliferative effect of the combination was reduced by only 8–10% vs. the inhibition induced by either EPI or CBD alone. We determined that the slight antagonism correlated positively to the registered dosage and decreased the extent of deoxyribose oxidative damage by using the enhanced chemiluminescent method with superoxide radicals. The therapeutic value of the combination of EPI plus CBD mainly consists of its high antiproliferative effect and the possibility to reduce the total dose on leukaemia-transformed cells by a factor of two. Supplemental data for this article is available online at https://doi.org/10.1080/13102818.2021.1996270 .
format	article
author	Margarita Zhelyazkova Nadya Hristova-Avakumova Lozan Todorov Georgi Momekov
author_facet	Margarita Zhelyazkova Nadya Hristova-Avakumova Lozan Todorov Georgi Momekov
author_sort	Margarita Zhelyazkova
title	In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin
title_short	In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin
title_full	In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin
title_fullStr	In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin
title_full_unstemmed	In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin
title_sort	in vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/561a735bda53473f927a09373311a1bb
work_keys_str_mv	AT margaritazhelyazkova invitroanticanceractivityandoxidativemoleculardamagebycannabidioladministeredaloneandincombinationwithepirubicin AT nadyahristovaavakumova invitroanticanceractivityandoxidativemoleculardamagebycannabidioladministeredaloneandincombinationwithepirubicin AT lozantodorov invitroanticanceractivityandoxidativemoleculardamagebycannabidioladministeredaloneandincombinationwithepirubicin AT georgimomekov invitroanticanceractivityandoxidativemoleculardamagebycannabidioladministeredaloneandincombinationwithepirubicin
_version_	1718425480845066240

In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin

Ejemplares similares